Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
BMC Nephrol ; 20(1): 191, 2019 05 28.
Article in English | MEDLINE | ID: mdl-31138132

ABSTRACT

BACKGROUND: Thrombophilia due to protein C (PC) and protein S (PS) deficiencies is highly prevalent among patients with stage 5 chronic kidney disease and is reported to arise due to extracorporeal circulation during hemodialysis (HD). This study aimed to evaluate the relationship between HD treatment and thrombophilia. METHODS: A total of 114 Japanese patients on maintenance HD (62 men, 52 women) were followed during 2008-2011. Their survival rates were compared against the duration of HD. Prior to each HD, coagulation/fibrinolysis parameters and PC and PS activities were measured using standard techniques. The patients were divided into two groups: Group 1, with PC and/or PS deficiencies (n = 32), and Group 2, without PC and PS deficiencies (n = 82). The influence of such deficiencies and duration of dialysis on survival was examined. Time-to-event analysis was applied using Kaplan-Meier estimates, and the log-rank test was proposed to test the equivalence of relative survival data. Hazard ratios and 95% confidence intervals (CI) were calculated. RESULTS: Of the 114 patients, 37 died (Group 1, 22; Group 2, 15). The hazard ratio (95% CI) was higher (p = 0.004) in Group 1 than Group 2. Gene analyses of PC and PS were performed in 14 patients from Group 1. No mutations in either protein were observed. We analyzed the causes of death in both groups; however, the estimated thrombophilia-related incidence of death could not be determined due to small sample size of HD patients. CONCLUSIONS: Our results suggest that PC and PS deficiencies may be related to survival in HD patients. However, this finding warrants additional research.


Subject(s)
Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/therapy , Protein C Deficiency/mortality , Protein S Deficiency/mortality , Renal Dialysis/mortality , Aged , Female , Follow-Up Studies , Humans , Kidney Failure, Chronic/blood , Male , Middle Aged , Protein C Deficiency/blood , Protein S Deficiency/blood , Protein S Deficiency/therapy , Renal Dialysis/trends , Survival Rate/trends
2.
J Vasc Access ; 16 Suppl 10: S46-9, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26349864

ABSTRACT

BACKGROUND: Arteriovenous graft (AVG) requires percutaneous transluminal angioplasty (PTA) to maintain its patency; however, bypass graft technique is often chosen in cases requiring PTA again within 3 months. We retrospectively examined whether bypass graft technique is effective for AVG. METHODS: The sample patient population consisted of 50 patients who underwent bypass graft technique on the venous side of the AVG between April 2012 and March 2014. The primary and assisted patencies of the technique were calculated, and compared by the type and length of the bypass graft. Kaplan-Meier method and log-rank test were used for the calculation and comparison of the patency, respectively. p<0.05 was considered statistically significant. RESULTS: The reasons for surgery were thrombotic occlusion (27 cases), frequent PTA (15 cases) and others (8 cases). Frequent PTA was conducted within 3 months in 22 of 27 thrombotic occlusion cases (making 37/50, or 74%). Moreover, thrombectomy was required in 34 cases (68%). The 1-year primary and 1-year assisted patencies of the technique were 6.5% and 72.6%, respectively. When the endpoint was frequent PTA within 3 months after the technique, 1-year primary patency was 45.9%. CONCLUSIONS: The 1-year primary patency of the technique was poor, and patency was hard to maintain without the assistance of PTA. Given that frequent PTA was conducted in 74% of patients, it may be a cause for the poor patency. Many cases required thrombectomies, which have the disadvantage of being more invasive than PTA. We concluded that bypass graft technique is not valuable for cases that received frequent PTA.


Subject(s)
Arteriovenous Shunt, Surgical/adverse effects , Blood Vessel Prosthesis Implantation/adverse effects , Graft Occlusion, Vascular/surgery , Renal Dialysis , Thrombectomy , Thrombosis/surgery , Aged , Angioplasty, Balloon , Arteriovenous Shunt, Surgical/instrumentation , Blood Vessel Prosthesis , Blood Vessel Prosthesis Implantation/instrumentation , Female , Graft Occlusion, Vascular/diagnosis , Graft Occlusion, Vascular/etiology , Graft Occlusion, Vascular/physiopathology , Humans , Kaplan-Meier Estimate , Male , Prosthesis Design , Renal Dialysis/adverse effects , Reoperation , Retrospective Studies , Risk Factors , Thrombectomy/adverse effects , Thrombosis/diagnosis , Thrombosis/etiology , Thrombosis/physiopathology , Time Factors , Treatment Outcome , Vascular Patency
3.
Nihon Jinzo Gakkai Shi ; 52(8): 1022-8, 2010.
Article in Japanese | MEDLINE | ID: mdl-21254698

ABSTRACT

Osteoprotegerin (OPG) inhibits interaction of the receptor-activator of nuclear factor-kappaB (RANK) ligand (RANKL) with its receptor RANK, which is expressed on osteoclasts. OPG appeared to accelerate vascular calcification in vitro by the inhibition of vascular osteoclast-like cells. On the contrary, early-onset arterial calcification was observed in OPG-deficient mice. We measured the coronary artery calcification score (CACS) and abdominal aortic calcification score (AAoCS) by multi-detector computed tomography in 30 pre-dialysis CKD patients (eGFR 20 mL/min on average). Biomarkers were measured, including serum OPG, soluble RANKL (sRANKL) and tartrate-resistant acid phosphatase (TRACP) -5b (the biomarker of osteoclasts independent of renal function). The median values of CACS and AAoCS were 54.4 and 1,088 Agatston units (AU), respectively. Serum OPG was increased and serum sRANKL was decreased. In a multivariate logistic regression analysis using CACS > or = 100 AU as the outcome variable, CACS was found to be positively correlated with serum corrected Ca x iP product and serum OPG, though it was not correlated with serum TRACP-5b. ROC curve analysis showed that the serum OPG cutoff value predicting CACS > or = 100 AU was 5.2 pmol/L (624 pg/mL). In a stepwise regression analysis, log (AAoCS + 1) was positively correlated with serum OPG alone, but it was not correlated with age, eGFR, serum albumin and bone alkaline phosphatase (BAP). No correlation was found between serum OPG and serum TRACP-5b. In conclusion, vascular calcification in pre-dialysis CKD patients was correlated with an increase in OPG, but was independent of serum TRACP-5b. The decrease in serum sRANKL may have been caused by the increase in OPG production.


Subject(s)
Acid Phosphatase/blood , Aorta, Abdominal , Aortic Diseases/diagnosis , Calcinosis/diagnosis , Coronary Disease/diagnosis , Coronary Vessels , Isoenzymes/blood , Osteoprotegerin/blood , Biomarkers/blood , Dialysis , Female , Humans , Logistic Models , Male , Osteoclasts/physiology , RANK Ligand/blood , Tartrate-Resistant Acid Phosphatase
SELECTION OF CITATIONS
SEARCH DETAIL
...